Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry

Breast Cancer Research and Treatment
Claudette FalatoTheodoros Foukakis

Abstract

Survival after loco-regional failure (LRF) of breast cancer was investigated at the population level. Using the Stockholm cancer registry, 2698 patients diagnosed with LRF between 1980 and 2014 were identified and divided into three cohorts by year of LRF diagnosis. Post-relapse event-free survival (EFS) and overall survival (OS) were analyzed separately in local and loco-regional relapses and compared across the cohorts by Kaplan-Meier method. Relative survival was estimated and Poisson regression models, adjusted for clinically relevant prognostic factors, were fitted for excess mortality ratio calculation. Age-related survival trends were also explored. Among 1922 patients diagnosed with local relapse, 1032 (54%) EFS events and 931 (48%) deaths were registered. A significant improvement in EFS (p < 0.001) and OS (p < 0.001) was demonstrated in tumors that recurred locally in the years 1990-1999 and 2000-2014 compared with 1980-1989, regardless of age at relapse (≤ 60 years; > 60 years). In women with loco-regional relapse, 557 out of 776 (72%) experienced a post-relapse event and 522 (67%) died. Significantly longer EFS and OS were seen over time in the whole group (p < 0.001 and p = 0.003, respectively) and in younger (p < ...Continue Reading

References

Mar 1, 1985·International Journal of Epidemiology·B MattssonA Wallgren
Apr 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C SchmoorM Schumacher
Sep 21, 2002·Lancet·Ian E Smith
Jul 26, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M WaeberUNKNOWN Swiss Group for Clinical Cancer Research (SAKK)
Dec 26, 2003·Statistics in Medicine·Paul W DickmanTimo Hakulinen
Feb 3, 2005·Journal of the National Cancer Institute·Davide MauriJohn P A Ioannidis
Oct 28, 2005·The New England Journal of Medicine·Donald A BerryUNKNOWN Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators
May 2, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Irene L WapnirNorman Wolmark
Dec 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitch DowsettRichard Peto
Apr 20, 2012·The Cochrane Database of Systematic Reviews·Lorenzo MojaRoberto D'Amico
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F CardosoUNKNOWN ESMO Guidelines Working Group
Jun 27, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C van LaarA C Voogd
Jan 21, 2014·The Lancet Oncology·Stefan AebiUNKNOWN CALOR investigators
Aug 27, 2014·PLoS Medicine·UNKNOWN PLOS Medicine Editors
Sep 2, 2014·Journal of Internal Medicine·L EmilssonJ F Ludvigsson
Jul 28, 2015·Lancet·UNKNOWN Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

❮ Previous
Next ❯

Citations

Jan 20, 2019·Breast Cancer Research and Treatment·Stephanie RobertsonJohan Hartman
Nov 9, 2019·Journal of Plastic Surgery and Hand Surgery·Emma HanssonLars Sandman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.